{
    "clinical_study": {
        "@rank": "58624", 
        "acronym": "ORCHESTRA", 
        "arm_group": [
            {
                "arm_group_label": "XELOX or FOLFOX regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "XELOX or FOLFOX regimen"
            }, 
            {
                "arm_group_label": "XELOX or FOLFOX regimen and maximal tumor debulking", 
                "arm_group_type": "Experimental", 
                "description": "XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare overall survival rates of colorectal cancer patients\n      with multi-organ metastases with an indication for first line systemic treatment randomized\n      for treatment with combination chemotherapy or treatment with combination chemotherapy and\n      additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE\n      and SBRT, depending on best clinical judgement according to a standardized treatment\n      algorithm. Our hypothesis is that maximal tumor debulking in addition to systemic treatment\n      with chemotherapy and biologicals will provide an improvement in progression free and\n      overall survival in this patient group."
        }, 
        "brief_title": "Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases", 
        "condition": "Multi-organ Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological documentation of cancer is required.\n\n          -  Indication for first line palliative systemic treatment for metastatic colorectal\n             cancer (mCRC).\n\n          -  Patients with CRC metastases in \u2265 2 different organs and\n\n               -  >3 extrahepatic metastases or\n\n               -  >5 hepatic metastases not located to one lobe or\n\n               -  \u22651 hepatic metastases and positive para-aortal or celiac lymph nodes or adrenal\n                  metastases\n\n               -  The primary tumor is excluded as metastatic site.\n\n          -  Tumor debulking can be achieved with local treatment modalities in at least 80% of\n             metastatic lesions\n\n          -  To meet the inclusion criteria a cytological analysis should be performed in case of\n             any uncertainty about the presence of a lesion e.g. a false positive or false\n             negative result on imaging.\n\n          -  Age \u00b3 18 years.\n\n          -  WHO performance status 0 - 1.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Adequate bone marrow, liver and renal function as assessed by the following\n             laboratory requirements to be conducted within 7 days prior to screening:\n\n               -  Hemoglobin \u2265 5.6 mmol/L;\n\n               -  Absolute neutrophil count (ANC) \u2265 1,500/mm3;\n\n               -  Platelet count \u2265 100*109/l;\n\n               -  Total bilirubin \u2264 1.5 times the upper limit of normal;\n\n               -  ALT and AST \u2264 2.5 x upper limit of normal (\u2264 5 x upper limit of normal for\n                  subjects with liver involvement of their cancer);\n\n               -  Albumine > 30 g/l;\n\n               -  Serum creatinine \u2264 1.5 x upper limit of normal or a MDRD \u2265 50 ml/min;\n\n               -  Prothrombin time or INR < 1.5 x ULN, unless coumarin derivates are used. Due to\n                  interactions with capecitabine, all patients using coumarin derivates will be\n                  treated with LMWH instead.\n\n               -  Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation\n                  therapy is allowed if this treatment can be interrupted as judged by the\n                  treating physician).\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Prior chemotherapy for metastatic disease.\n\n          -  Prior (neo-)adjuvant chemotherapy for non-metastatic disease < 6 months after last\n             treatment and first detection of metastasis.\n\n          -  Candidates for HIPEC.\n\n          -  Patients with liver metastases only\n\n          -  Evidence of brain metastases.\n\n          -  Other malignant diseases\n\n          -  History of cardiac disease:\n\n               -  Congestive heart failure >NYHA class 2;\n\n               -  Active Coronary Artery Disease (defined as myocardial infarction within 6 months\n                  prior to screening);\n\n               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin\n                  are permitted).\n\n          -  Uncontrolled hypertension. Blood pressure must be \u2264160/95 mmHg at the time of\n             screening on a stable antihypertensive regimen. Blood pressure must be stable on at\n             least 3 separate measurements on at least 2 separate days.\n\n          -  Uncontrolled infections (> grade 2 NCI-CTC version 4.0).\n\n          -  Pregnant or breast-feeding women. Women of childbearing potential must have a\n             negative pregnancy test performed within 7 days of the start of treatment. Both men\n             and women enrolled in this trial must agree to use adequate barrier birth control\n             measures (e.g., cervical cap, condom, and diaphragm) or intrauterine device during\n             the course of the trial. Oral birth control methods alone will not be considered\n             adequate on this study, because of the potential pharmacokinetic interaction between\n             study drug and oral contraceptives. Concomitant use of oral and barrier\n             contraceptives is advised.\n\n          -  Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy\n             during the study or within 4 weeks of the start of study drug.\n\n          -  Concomitant use of dexamethasone, anti-convulsants and anti-arrhythmic drugs other\n             than digoxin or beta blockers.\n\n          -  Severe allergy for contrast media not controlled with premedication.\n\n          -  Substance abuse, medical, psychological or social conditions that may interfere with\n             the subject's participation in the study or evaluation of the study results.\n\n          -  Any condition that is unstable or could jeopardize the safety of the subject and\n             their compliance in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "478", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792934", 
            "org_study_id": "2012-073"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "XELOX or FOLFOX regimen", 
                    "XELOX or FOLFOX regimen and maximal tumor debulking"
                ], 
                "intervention_name": "XELOX regimen according to standard procedures", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "XELOX or FOLFOX regimen", 
                    "XELOX or FOLFOX regimen and maximal tumor debulking"
                ], 
                "intervention_name": "FOLFOX regimen according to standard procedures", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "XELOX or FOLFOX regimen and maximal tumor debulking", 
                "intervention_name": "Surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "XELOX or FOLFOX regimen and maximal tumor debulking", 
                "intervention_name": "radiofrequency ablation (RFA)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "XELOX or FOLFOX regimen and maximal tumor debulking", 
                "intervention_name": "transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "XELOX or FOLFOX regimen and maximal tumor debulking", 
                "intervention_name": "stereotactic body radiation therapy (SBRT)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "XELOX or FOLFOX regimen", 
                    "XELOX or FOLFOX regimen and maximal tumor debulking"
                ], 
                "description": "may be added to both regimens according to standard procedures", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "XELOX or FOLFOX regimen", 
                    "XELOX or FOLFOX regimen and maximal tumor debulking"
                ], 
                "description": "at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy", 
                "intervention_name": "tumor biopsy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Oxaliplatin", 
                "Bevacizumab", 
                "Fluorouracil", 
                "Leucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "h.verheul@vumc.nl", 
                    "last_name": "H.M.W. Verheul, MD, PhD", 
                    "phone": "0031-20-4444321"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "NL-1081 HV"
                    }, 
                    "name": "VU Medical Center"
                }, 
                "investigator": {
                    "last_name": "H.M.W. Verheul, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "c.verhoef@erasmusmc.nl", 
                    "last_name": "C. Verhoef, MD PhD", 
                    "phone": "0031 (0)10 7040704"
                }, 
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "NL-3075 EA"
                    }, 
                    "name": "Erasmus University Medical Center"
                }, 
                "investigator": {
                    "last_name": "C. Verhoef, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.", 
        "overall_contact": {
            "email": "h.verheul@vumc.nl", 
            "last_name": "H.M.W. Verheul, MD PhD", 
            "phone": "0031 (0)20 4444321"
        }, 
        "overall_official": {
            "affiliation": "VU University Medical Center", 
            "last_name": "H.M.W. Verheul, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "from date of study inclusion until the date of death or until the end of follow up, assessed up to 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792934"
        }, 
        "responsible_party": {
            "investigator_affiliation": "VU University Medical Center", 
            "investigator_full_name": "H.M.W. Verheul", 
            "investigator_title": "Head Department Medical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival rates", 
                "safety_issue": "No", 
                "time_frame": "date of study inclusion to the first event defined as local recurrence or progression, distant recurrence or death from any cause assessed up to 10 years"
            }, 
            {
                "measure": "Response rates", 
                "safety_issue": "No", 
                "time_frame": "assessed every 3 months, after a follow up of 3 years assessed every 6 months"
            }, 
            {
                "measure": "Safety and efficacy of the additional local treatment measured by number of serious adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "assessed after inclusion of 25, 50 and 100 patients, after 30% of the patients are included in the study for 12 months and after the end of follow up, assessed up to 10 years"
            }
        ], 
        "source": "VU University Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Erasmus Medical Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "VU University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}